Jungwoo Heparin Injection (Heparin Sodium)

Adult administration

Typically administered intravenously or added to the blood during extracorporeal circulation. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Administer 1,000 to 5,000 IU of heparin sodium before initiating dialysis, and continuously administer 500 to 1,500 IU per hour or intermittently add 500 to 1,500 IU every hour after the start of dialysis. (2) Local heparinization

This medication is a very potent drug and should only be used under the strict supervision of a physician. It should be administered with caution in patients with diseases that have a high risk of bleeding, as this drug can cause bleeding in almost any part of the body. Severe bleeding such as adrenal hemorrhage, ovarian hemorrhage, and retroperitoneal hemorrhage, which can lead to acute adrenal insufficiency, may occur. In addition, the benzyl alcohol component in this drug can cause fatal respiratory problems in premature infants, so it should not be used in newborns or premature babies. It should not be administered to individuals with an allergy to this drug or its components, patients with abnormal coagulation test results, patients with bleeding, patients at high risk of bleeding, patients with severe liver or kidney disease, patients who have recently undergone central nervous system or eye surgery, patients who have received spinal or epidural anesthesia, and patients with a history of thrombocytopenia. Careful administration is required for pregnant women in late pregnancy, children, the elderly, alcoholics, and patients with certain diseases, and coagulation status should be frequently monitored and immediate action taken if abnormalities are found. During the administration of this drug, bleeding symptoms and platelet counts must be closely monitored, and if there is a rapid decrease in platelets, administration should be stopped immediately. If anticoagulant effect is excessively reduced or rapid neutralization of anticoagulation is needed, the antidote protamine sulfate should be used. This drug can interact with other medications, so caution should be exercised particularly when used with analgesics, anti-inflammatory drugs, anticoagulants, and thrombolytics, as there is an increased risk of bleeding. During pregnancy or breastfeeding, special care should be taken due to the risk of bleeding in the uterus and placenta, and the benzyl alcohol component can also affect the fetus and newborn. In cases of overdose, bleeding complications may occur, and an antidote must be administered immediately to neutralize the effects; injection methods that carry a high risk of bleeding, such as intramuscular injection, should be avoided.

Serious side effects

• Urticaria, angioedema, dyspnea, shock → severe allergic reaction
• Bleeding → increased risk of bleeding and fatal hemorrhage
• Thrombocytopenia → immune-mediated thrombosis and thrombocytopenia
• Liver dysfunction (elevated ALT, AST, γ-GTP, LDH) → hepatic impairment
• Hypotension, cyanosis → severe allergic reaction
• Adrenal hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage → acute adrenal insufficiency and hemorrhage
• Thrombocytopenia and thrombosis (HI

Mild side effects

Itching, urticaria, chills, fever, rhinitis, bronchial asthma, tearing, conjunctivitis, cyanosis, tachycardia, pressure sensation, angioedema, nausea, vomiting, hypotension, bronchospasm, hair loss, leukopenia, hemorrhagic necrosis, hypoaldosteronism, osteoporosis, rebound effect, hyperlipidemia, renal function suppression, local pain hematoma due to subcutaneous or intramuscular injection, priapism, diabetes, hyperkalemia, hypochloremia, metabolic acidosis, lipase

This drug should be stored in a sealed container that can block light if it is for internal use. For export, it should be kept in a sealed container in a cool place below 30 degrees Celsius, taking care not to freeze.

Appearance

A colorless to pale yellow transparent liquid in a brown glass vial injection

Package unit

5mL x 10 vials